Ranbaxy, punished by a US court this month for quality violations in drug manufacturing, now faces heat at home. The health ministry has asked the drug controller general of India to examine the documents, dossiers and the approval given to the largest pharma firm of the country.

"Regulators will evaluate all the documents related to Ranbaxy to see weather the quality control mechanism has been taken care of fully as per norms in seeking approvals by Ranbaxy," a senior health ministry officer told Governance Now.

A report is expected to be prepared in a month. However, the question remains why Indian authorities took no action when there was uproar in parliament over this issue after US FDA leveled charges against Ranbaxy in 2008.

The ministry had probed the matter in late 2008 but decided not to ban the drugs manufactured at two of the Ranbaxy facilities at Dewas and Paonta Sahib. In fact, the drug controller had inspected the two facilities and found nothing objectionable.